Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.
about
Targeting of erbB3 receptor to overcome resistance in cancer treatmentNuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.AXL mediates resistance to cetuximab therapyHER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsRegulation of therapeutic resistance in cancers by receptor tyrosine kinases.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.Immunohistochemical Assessment of HER3 Expression in Odontogenic CystsEmerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyA comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
P2860
Q26864668-0C28789F-2C92-4849-BF45-578E6C1B712AQ33578803-EDC47027-5942-4E51-9289-16C373A9259AQ34204829-96209DB2-A09C-44BB-81CB-02F69576241EQ35201923-02BE3E77-0FBC-4F6D-87C6-918AAE439317Q36879506-65AE7FA2-96C3-4358-BC02-7D226B663A84Q37190106-1FCFA972-0192-4E58-93E7-A02A3BC12CE0Q37274810-83A55DE4-F581-431E-94B7-C98D25A4DB44Q38382793-72C701F3-68D2-43C4-B70E-B452E0DBA22CQ38623361-082FDD22-8D04-43B4-ADF2-7ADB0092A5DBQ38929801-9C1A89B4-91A4-497A-B383-1D5B3AEA0902Q38945259-FFD106C8-7B1A-471D-BE17-97AEF650BD60Q47158524-65EEEB39-90E2-4689-B3B7-7977ED2532B9Q47203450-F826DEB8-71EF-482C-9E51-846172952DBDQ47396247-FDE35495-11ED-4382-A9B4-1E7DA34A949BQ47591626-26D04572-54F3-46C7-8607-77C464A979F1
P2860
Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human epidermal growth factor ...... g and head and neck carcinoma.
@en
Human epidermal growth factor receptor 3
@nl
type
label
Human epidermal growth factor ...... g and head and neck carcinoma.
@en
Human epidermal growth factor receptor 3
@nl
prefLabel
Human epidermal growth factor ...... g and head and neck carcinoma.
@en
Human epidermal growth factor receptor 3
@nl
P2093
P2860
P1433
P1476
Human epidermal growth factor ...... g and head and neck carcinoma.
@en
P2093
Albert van der Kogel
Chunrong Li
Deric L Wheeler
Eric A Armstrong
Shyhmin Huang
Toni M Brand
P2860
P577
2013-09-01T00:00:00Z